CN107645957A - 治疗癌症的hsp90抑制剂和pd‑1抑制剂的组合疗法 - Google Patents

治疗癌症的hsp90抑制剂和pd‑1抑制剂的组合疗法 Download PDF

Info

Publication number
CN107645957A
CN107645957A CN201680013008.9A CN201680013008A CN107645957A CN 107645957 A CN107645957 A CN 107645957A CN 201680013008 A CN201680013008 A CN 201680013008A CN 107645957 A CN107645957 A CN 107645957A
Authority
CN
China
Prior art keywords
inhibitor
cancer
hydroxy
hsp90
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680013008.9A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·普罗亚
P·E·拉奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of CN107645957A publication Critical patent/CN107645957A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680013008.9A 2015-02-09 2016-02-09 治疗癌症的hsp90抑制剂和pd‑1抑制剂的组合疗法 Pending CN107645957A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113807P 2015-02-09 2015-02-09
US62/113,807 2015-02-09
PCT/US2016/017075 WO2016130502A1 (en) 2015-02-09 2016-02-09 Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
CN107645957A true CN107645957A (zh) 2018-01-30

Family

ID=55405477

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680013008.9A Pending CN107645957A (zh) 2015-02-09 2016-02-09 治疗癌症的hsp90抑制剂和pd‑1抑制剂的组合疗法

Country Status (12)

Country Link
US (1) US11497733B2 (cg-RX-API-DMAC7.html)
EP (1) EP3256161A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018504446A (cg-RX-API-DMAC7.html)
KR (1) KR20170113664A (cg-RX-API-DMAC7.html)
CN (1) CN107645957A (cg-RX-API-DMAC7.html)
AU (1) AU2016219497A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017016973A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976072A1 (cg-RX-API-DMAC7.html)
HK (1) HK1244436A1 (cg-RX-API-DMAC7.html)
IL (1) IL253905A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017010299A (cg-RX-API-DMAC7.html)
WO (1) WO2016130502A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CA3067454A1 (en) * 2017-06-20 2018-12-27 Tarveda Therapeutics, Inc. Combination therapies comprising targeted therapeutics
FI3646869T3 (fi) * 2017-06-30 2025-09-17 Taiho Pharmaceutical Co Ltd Solunsalpaajahoito atsabisykloyhdisteellä syövän hoitamiseksi
WO2019088016A1 (ja) * 2017-10-30 2019-05-09 宇部興産株式会社 置換ジヒドロピロロピラゾール化合物および免疫療法剤が組み合わせて投与される医薬組成物
JP2021525766A (ja) * 2018-06-01 2021-09-27 ターベダ セラピューティクス インコーポレイテッドTarveda Therapeutics,Inc. 併用療法
EP3878446A1 (en) * 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
KR20230055998A (ko) * 2021-10-19 2023-04-26 오가노이드사이언스 주식회사 암 치료 또는 예방용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641010A (zh) * 2007-01-26 2010-02-03 路易斯维尔大学研究基金会公司 用作疫苗的外来体组分的修饰
US20110300186A1 (en) * 2010-04-14 2011-12-08 Battelle Memorial Institute Functionalized Nano- and Micro-materials for Medical Therapies
WO2013170159A1 (en) * 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US20050176024A1 (en) 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA)
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
US8742133B2 (en) 2007-08-13 2014-06-03 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
AU2009215168A1 (en) 2008-02-12 2009-08-20 Dana-Farber Cancer Institute Fish assay for EML4 and ALK fusion in lung cancer
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2729144A2 (en) 2011-07-07 2014-05-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
AU2014309199B2 (en) 2013-08-20 2018-04-19 Merck Sharp & Dohme Llc Treating cancer with a combination of a PD-1 antagonist and dinaciclib
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
UA122479C2 (uk) * 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641010A (zh) * 2007-01-26 2010-02-03 路易斯维尔大学研究基金会公司 用作疫苗的外来体组分的修饰
US20110300186A1 (en) * 2010-04-14 2011-12-08 Battelle Memorial Institute Functionalized Nano- and Micro-materials for Medical Therapies
WO2013170159A1 (en) * 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
WO2013173223A1 (en) * 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Also Published As

Publication number Publication date
AU2016219497A1 (en) 2017-08-31
JP2018504446A (ja) 2018-02-15
WO2016130502A1 (en) 2016-08-18
KR20170113664A (ko) 2017-10-12
IL253905A0 (en) 2017-10-31
US11497733B2 (en) 2022-11-15
MX2017010299A (es) 2017-11-10
BR112017016973A2 (pt) 2018-04-03
HK1244436A1 (zh) 2018-08-10
CA2976072A1 (en) 2016-08-18
US20180064689A1 (en) 2018-03-08
EP3256161A1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
US11497733B2 (en) Combination therapy of HSP90 inhibitors and PD-1 inhibitors for treating cancer
US11891450B2 (en) Anti-CD47 agent-based treatment of CD20-positive cancer
CN111032082B (zh) Her2阳性癌症的治疗
EP4376874B1 (en) Chimeric tim4 receptors and uses thereof
Ware et al. Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell–and CXCR3-dependent manner
KR20230059792A (ko) 암 치료를 위한 조합
JP7809324B2 (ja) sEphB4-HSA融合タンパク質を用いたがんの治療
US20150202287A1 (en) Combination therapies comprising anti-erbb3 agents
KR20210031679A (ko) 수모-활성화 효소 저해제 및 항-cd20 항체의 투여
US11419894B2 (en) Modified natural killer cells for the treatment of cancer
JP2025542076A (ja) がん治療のためのチロシンキナーゼ阻害剤と炎症誘発剤の併用
US20220025061A1 (en) Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist
WO2018075447A1 (en) Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
JP2025531789A (ja) がん治療のためのshp-1阻害剤
AU2018289354A1 (en) Combination therapies comprising targeted therapeutics
US12599620B2 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
WO2024218649A2 (en) Combination of a protein kinase inhibitor with immunomodulatory agents
US20220257777A1 (en) Hsp90-binding conjugates and combination therapies thereof
CN118043067A (zh) 嵌合tim4受体及其用途
WO2024196822A1 (en) Compositions and methods for ameliorating adverse effects of therapies
WO2025021587A1 (en) Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof
Diep Therapeutic Targeting of AXL/Gas6 Signaling in Metastatic and Primary Cancer
JPWO2020027217A1 (ja) がんの治療及び/又は予防のための医薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180130